On behalf of the Canadian Arthritis Patient Alliance (CAPA), we welcomed the opportunity to provide feedback on the draft guidance for biosimilar biologic drugs. Ensuring that patient perspectives are included in the development of policies is essential to improving...
Canadian Arthritis Patient Alliance (CAPA) was offered an opportunity to provide feedback related to Health Canada’s Consultation: Handbook for healthcare professionals on biosimilar biologic drugs. CAPA has a Medical Advisory Committee (MAC), and all of our resources...
Access to the right medicines is an important component in managing arthritis. In Canada, the Patented Medicines Prices Review Board (PMPRB) plays a key role in drug pricing in Canada. On July 1, 2020, the newly amended Patented Medicines Regulations will come into...
English 
Français du Canada